Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Executive Summary
Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.
You may also be interested in...
The Top Five Pharma Stories Of 2023
The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, we take a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.
The Top Five Pharma Stories Of 2023
The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, Scrip takes a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.
BIO Notebook: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients
GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.